Proposal for the management of COVID-19-associated coagulopathy in children

Propuesta para el manejo de la coagulopatía asociada a COVID-19 en niños

Susana Palomino-Nolasco^{1*}, Gerardo M. Pacheco-González¹ and Claudia V. Saldaña-Díaz²

¹Faculty of Medicine, Universidad Privada San Juan Bautista; ²Research Functional Unit, Instituto Nacional Materno Perinatal. Lima, Peru

Dear editor,

After having reviewed the article written by Ávila et al. "Proposal for the management of COVID-19-associated coagulopathy in children" we considered highlighting in three points the thrombotic complications due to coronavirus disease 2019 (COVID-19) associated with acute respiratory distress syndrome that require an anticoagulant therapeutic strategy.

- Pulmonary inflammation generates damage to the pulmonary vasculature and triggers a thrombosis that is followed by a hypercoagulable state that involves thrombocytopenia and fibrinogen and D-dimer elevated levels¹.
- Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) activates the fibrinolytic system in an abnormal form, since intrapulmonary fibrin deposits are replaced by an abnormal fibrin that is responsible for coagulopathy².
- Prophylactic anticoagulation with enoxaparin is necessary, given that a syndrome similar to

Kawasaki disease has been described in children and adolescents³.

Thrombotic complications and lung damage due to SARS-CoV-2 infection are related, which is why prophylactic anticoagulant management is required.

Funding

The authors declare that there was no funding.

Conflict of interests

The authors declare that there is no conflict of interests.

References

1. Wool GD, Miller JL. The Impact of COVID-19 Disease on Platelets and Coagulation. *Pathobiology*. 2021;88(1):15-27.
2. Levi M, Thachil J. Coronavirus Disease 2019 Coagulopathy: Disseminated Intravascular Coagulation and Thrombotic Microangiopathy—Either, Neither, or Both. *Semin Thromb Hemost*. October 2020;46(07):781-4.
3. Cervera Ubierna A. Tratamiento de la infección por SARS-CoV-2. *Acta Pediátrica México*. 29 June 2020;41(4S1):121.

Correspondence:

*Susana Palomino-Nolasco

E-mail: Susan.palomino19@gmail.com

Date of reception: 22-06-2021

Date of acceptance: 06-10-2021

DOI: 10.24875/GMM.M21000630

Gac Med Mex. 2021;157:639

Contents available at PubMed

www.gacetamedicademexico.com

0016-3813/© 2021 Academia Nacional de Medicina de México, A.C.. Published by Permanyer. This is an open access article under the CC BY-NC-ND license (<http://creativecommons.org/licenses/by-nc-nd/4.0/>).